JAMIE ROMERO: Open Payments
NPI 1225783848 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$466 in 20 payments from 9 companies in 2025. Trend: 2023 $285 · 2024 $368 · 2025 $466
Food & beverage: $466
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $83 |
| Novartis Pharmaceuticals Corporation | 3 | $70 |
| Otsuka America Pharmaceutical, Inc. | 3 | $66 |
| Calliditas Therapeutics US Inc. | 2 | $63 |
| AKEBIA THERAPEUTICS INC | 2 | $54 |
| Ardelyx, Inc. | 2 | $43 |
| AstraZeneca Pharmaceuticals LP | 2 | $39 |
| Novo Nordisk Inc | 1 | $24 |
| Vifor Pharma, Inc. | 1 | $23 |
Products named: Kerendia, Vanrafia, TARPEYO, Vafseo, JYNARQUE, IBSRELA, Wegovy, Veltassa.
Industry payments across MD — which companies pay providers there.
